Tango reports 82% tumor response in pancreatic cancer combo trial

· Health · United States

Tango Therapeutics reported that an experimental drug combination produced tumor responses in 82% of patients with a certain type of advanced pancreatic cancer. The data came as the ESMO congress opened in Madrid, and Endpoints described the combination as clearing the bar set by Revolution Medicines' pancreatic cancer results while showing striking promise. Tango's readout was among the most anticipated at the meeting, alongside the Moderna-Merck vaccine data that leaked early. Pancreatic cancer is among the most aggressive and treatment-resistant tumors, and the field has seen little progress for years, making the response rate notable for a disease where effective options are scarce.

Why it matters：A high response rate in one of oncology's hardest targets would draw attention and capital to RAS-directed and combination approaches in pancreatic cancer, a disease with few wins.

Key points

  • The 82% response rate applies to a certain type of advanced pancreatic cancer.
  • Data were presented as the ESMO congress opened in Madrid.
  • Endpoints framed the result as clearing Revolution Medicines' bar.

Sources (original reporting)

More stories from this day